Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Laparoscopic and open colectomy and proctectomy; stapler, energy, and robotics call point. Main billing specialties: general surgery and colon & rectal surgery.
Medicare fee-for-service colorectal resection cases in the 50 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (230 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 16 | 4,592−1.4%/yr | −1.4%/yr | 1.40.9× | 0% | 5,470 in 2030+3%/yr |
| Texas | 15 | 3,636−5.1%/yr | −5.1%/yr | 1.71.1× | 0% | 3,880 in 2030+1.1%/yr |
| Florida | 14 | 3,627−6.3%/yr | −6.3%/yr | 1.71.0× | 0% | 3,630 in 20300%/yr |
| New York | 15 | 2,669−5%/yr | −5%/yr | 1.50.9× | 0% | 2,770 in 2030+0.6%/yr |
| Pennsylvania | 12 | 2,424−5.6%/yr | −5.6%/yr | 1.81.1× | 0% | 2,120 in 2030−2.2%/yr |
| Illinois | 7 | 2,192−5.2%/yr | −5.2%/yr | 1.61.0× | 0% | 1,930 in 2030−2.1%/yr |
| Ohio | 8 | 1,916−5.8%/yr | −5.8%/yr | 1.81.1× | 0% | 2,040 in 2030+1.1%/yr |
| North Carolina | 8 | 1,589−6.5%/yr | −6.5%/yr | 1.61.0× | 0% | 1,360 in 2030−2.6%/yr |
| New Jersey | 8 | 1,527−3%/yr | −3%/yr | 1.50.9× | 0% | 1,740 in 2030+2.2%/yr |
| Virginia | 8 | 1,510−4.9%/yr | −4.9%/yr | 1.50.9× | 0% | 1,480 in 2030−0.3%/yr |
| Georgia | 9 | 1,488−6.4%/yr | −6.4%/yr | 1.81.1× | 0% | 1,450 in 2030−0.4%/yr |
| Massachusetts | 10 | 1,485−3.1%/yr | −3.1%/yr | 1.61.0× | 0% | 1,660 in 2030+1.9%/yr |
| Michigan | 3 | 1,300−11%/yr | −11%/yr | 1.61.0× | 0% | 1,170 in 2030−1.7%/yr |
| Tennessee | 8 | 1,264−5.6%/yr | −5.6%/yr | 1.81.1× | 0% | 1,230 in 2030−0.4%/yr |
| Missouri | 6 | 1,232−5.9%/yr | −5.9%/yr | 2.01.2× | 0% | 1,250 in 2030+0.2%/yr |
| Arizona | 9 | 1,209−3.2%/yr | −3.2%/yr | 1.71.0× | 0% | 1,270 in 2030+0.9%/yr |
| Indiana | 3 | 1,174−6.4%/yr | −6.4%/yr | 1.71.0× | 0% | 1,190 in 2030+0.2%/yr |
| Maryland | 9 | 1,152−4.6%/yr | −4.6%/yr | 1.30.8× | 0% | 1,300 in 2030+2.1%/yr |
| South Carolina | 6 | 1,082−4.9%/yr | −4.9%/yr | 1.61.0× | 0% | 1,180 in 2030+1.5%/yr |
| Washington | 4 | 1,073−5.1%/yr | −5.1%/yr | 1.40.9× | 0% | 1,020 in 2030−0.9%/yr |
| Wisconsin | 1 | 955−4%/yr | −4%/yr | 1.71.1× | 0% | 1,070 in 2030+1.9%/yr |
| Oklahoma | 7 | 875−4%/yr | −4%/yr | 1.81.1× | 0% | 740 in 2030−2.7%/yr |
| Minnesota | 1 | 849−4.5%/yr | −4.5%/yr | 1.91.2× | 0% | 1,120 in 2030+4.8%/yr |
| Kentucky | 1 | 825−7.8%/yr | −7.8%/yr | 1.81.1× | 0% | 700 in 2030−2.7%/yr |
| Kansas | 4 | 782−3.5%/yr | −3.5%/yr | 2.01.2× | 0% | 730 in 2030−1.1%/yr |
| Alabama | 7 | 775−8.2%/yr | −8.2%/yr | 1.81.1× | 0% | 760 in 2030−0.3%/yr |
| Louisiana | 3 | 766−7.5%/yr | −7.5%/yr | 1.91.2× | 0% | 690 in 2030−1.6%/yr |
| Colorado | 2 | 764−2.7%/yr | −2.7%/yr | 1.61.0× | 0% | 860 in 2030+2.1%/yr |
| Mississippi | 5 | 704−8.2%/yr | −8.2%/yr | 1.91.2× | 0% | 680 in 2030−0.7%/yr |
| Arkansas | 3 | 698−6%/yr | −6%/yr | 1.91.2× | 0% | 680 in 2030−0.3%/yr |
| Oregon | 1 | 627−4.1%/yr | −4.1%/yr | 1.50.9× | 0% | 710 in 2030+2%/yr |
| Iowa | 3 | 615−5.1%/yr | −5.1%/yr | 1.40.9× | 0% | 570 in 2030−1.3%/yr |
| Nebraska | 2 | 506−3.8%/yr | −3.8%/yr | 2.01.2× | 0% | 480 in 2030−0.8%/yr |
| Connecticut | 2 | 469−8.4%/yr | −8.4%/yr | 1.50.9× | 0% | 480 in 2030+0.5%/yr |
| Nevada | 3 | 409−3.9%/yr | −3.9%/yr | 1.50.9× | 0% | 440 in 2030+1.1%/yr |
| Utah | 1 | 352−0.3%/yr | −0.3%/yr | 1.61.0× | 0% | 360 in 2030+0.4%/yr |
| Montana | 2 | 340−0.4%/yr | −0.4%/yr | 1.81.1× | 0% | 360 in 2030+1%/yr |
| New Hampshire | 1 | 334−4.2%/yr | −4.2%/yr | 1.50.9× | 0% | 420 in 2030+3.9%/yr |
| Idaho | 0 | 307−1.1%/yr | −1.1%/yr | 1.50.9× | 0% | 320 in 2030+0.6%/yr |
| South Dakota | 1 | 271−6.1%/yr | −6.1%/yr | 2.11.3× | 0% | 320 in 2030+2.7%/yr |
| West Virginia | 0 | 265−9.2%/yr | −9.2%/yr | 1.30.8× | 0% | 200 in 2030−4.7%/yr |
| Maine | 1 | 264−7.9%/yr | −7.9%/yr | 1.71.0× | 0% | 170 in 2030−7.1%/yr |
| Delaware | 2 | 264−6.1%/yr | −6.1%/yr | 1.61.0× | 0% | 340 in 2030+4.1%/yr |
| North Dakota | 0 | 196−4.4%/yr | −4.4%/yr | 2.01.2× | 0% | 230 in 2030+2.4%/yr |
| District of Columbia | 1 | 196−6.3%/yr | −6.3%/yr | 3.21.9× | 0% | 170 in 2030−2.1%/yr |
| New Mexico | 0 | 182−11%/yr | −11%/yr | 0.80.5× | 0% | 170 in 2030−1.5%/yr |
| Alaska | 0 | 161−1.8%/yr | −1.8%/yr | 1.30.8× | 0% | 170 in 2030+1.2%/yr |
| Vermont | 0 | 141+1.5%/yr | +1.5%/yr | 1.30.8× | 0% | 150 in 2030+1%/yr |
| Rhode Island | 0 | 116−12%/yr | −12%/yr | 1.30.8× | 0% | 230 in 2030+12%/yr |
| Wyoming | 0 | 105−1.1%/yr | −1.1%/yr | 1.00.6× | 0% | 110 in 2030+0.6%/yr |
Professional codes (what the surgeon bills): CPT 44204, 44205, 44207, 44140, 44145, 44160, 45395, 45397; the hospital bills MS-DRG 329, 330, 331.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 184 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 29 companies. The most active:
Product codes: GAG (stapler, surgical), GDW (staple, implantable), NAY (system, surgical, computer controlled instrument). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 68% of the cases CMS names in California; 13 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Hernia repair | 2,306 | 187,629−3%/yr | −3%/yr | 210,200 in 2030+1.9%/yr |
| Cholecystectomy & appendectomy | 2,560 | 131,995−5.4%/yr | −5.4%/yr | 140,500 in 2030+1%/yr |
| Antireflux & hiatal hernia surgery | 375 | 23,396−1.8%/yr | −1.8%/yr | 28,800 in 2030+3.5%/yr |
| Breast reconstruction | 66 | 13,660−6.4%/yr | −6.4%/yr | 17,400 in 2030+4.1%/yr |
| Bariatric surgery | 15 | 4,952−17%/yr | −17%/yr | 3,750 in 2030−4.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 8 companies reported engagement with surgeons in the covered states worth $11M in consulting, speaking, meals and travel tied to these products, about $49K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.